+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis



Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis



Antimicrobial Agents and ChemoTherapy 51(4): 1253-1258



The reformulation of amphotericin B (AMB) into a lipid complex (AMB lipid complex [ABLC]) or liposomal carrier (liposomal AMB [L-AMB]) changes the rate and extent of drug distribution to the lung. The importance of pharmacokinetic differences among the various lipid AMB formulations in the treatment of invasive pulmonary aspergillosis (IPA) remains unknown. We compared the kinetics of AMB lung accumulation and fungal clearance of ABLC- and L-AMB-treated mice with acute IPA. BALB/c mice were immunosuppressed with cyclophosphamide and cortisone before intranasal inoculation with 1.5x10(6) Aspergillus fumigatus 293 conidia. ABLC or L-AMB was administered in daily intravenous doses (1, 5, or 10 mg/kg of body weight), starting 12 h after infection and continuing until day 5. At predetermined times (0, 24, 72, and 120 h), mice were euthanized, and lungs were harvested for determinations of lung fungal burdens (quantitative PCR) and total AMB lung tissue concentrations. Both ABLC and L-AMB were effective at reducing lung fungal burdens at doses of >or=5 mg/kg/day. Clearance of A. fumigatus during the first 24 h was associated with AMB tissue concentrations of >4 microg/g. At 5 mg/kg/day, ABLC produced a more rapid fungal clearance than did L-AMB, but at the end of therapy, fungal burden reductions were similar for both formulations and were not improved with higher dosages. These data suggest that ABLC delivers active AMB to the lung more rapidly than does L-AMB, resulting in faster Aspergillus clearance in an experimental model of IPA. However, pharmacodynamic differences between the two formulations were less apparent when mice were dosed at 10 mg/kg/day.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 013051267

Download citation: RISBibTeXText

PMID: 17261624

DOI: 10.1128/aac.01449-06


Related references

Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an in vitro model of invasive pulmonary aspergillosis. Antimicrobial Agents and ChemoTherapy 54(8): 3432-3441, 2010

Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis. Antimicrobial Agents and ChemoTherapy 54(3): 1298-1304, 2010

Budget impact analysis of liposomal amphotericin B and amphotericin B lipid complex in the treatment of invasive fungal infections in the United States. Applied Health Economics and Health Policy 12(1): 85-93, 2014

Budget Impact Analysis Of Liposomal Amphotericin B And Amphotericin B Lipid Complex For Treating Invasive Fungal Infections In Hospitalized Patients. Value in Health 16(3): A83-A84, 2013

Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy. Cancer 112(6): 1282-1287, 2008

Therapeutic efficacy of amphotericin b lipid complex , amphotericin b colloidal dispersion , liposomal amphotericin b , and conventional amphotericin b in murine coccicioidomycosis. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 42: 372, 2002

Pharmacoeconomic analysis of amphotericin B lipid complex versus liposomal amphotericin B in the treatment of fungal infections. Pharmacoeconomics 22(5): 301-310, 2004

Comparative study on the efficacy of liposomal amphotericin B and voriconazole in a murine pulmonary aspergillosis model. ChemoTherapy 55(2): 105-113, 2009

Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy study. Clinical Therapeutics 29(9): 1980-1986, 2007

Efficacy of single-dose liposomal amphotericin B or micafungin prophylaxis in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrobial Agents and ChemoTherapy 52(11): 4178-4180, 2008

Efficacy of SPK-843, a novel polyene antifungal, in comparison with amphotericin B, liposomal amphotericin B, and micafungin against murine pulmonary aspergillosis. Antimicrobial Agents and ChemoTherapy 52(5): 1868-1870, 2008

The comparative toxicity and concentrations of intravitreally administered amphotericine B deoxycholate , amphotericin B lipid complex , and liposomal amphotericin B in a rabbit model. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 40: 396, 2000

Efficacy of aerosolized amphotericin B desoxycholate and liposomal amphotericin B in the treatment of invasive pulmonary aspergillosis in severely immunocompromised rats. Journal of Antimicrobial ChemoTherapy 48(1): 89-95, 2001

In-vitro antifungal activity of liposomal nystatin in comparison with nystatin, amphotericin B cholesteryl sulphate, liposomal amphotericin B, amphotericin B lipid complex, amphotericin B desoxycholate, fluconazole and itraconazole. Journal of Antimicrobial ChemoTherapy 44(3): 397-401, 1999

Remission of invasive sinusal and pulmonary aspergillosis with liposomal amphotericin B in a patient with chronic lymphatic leukemia following failure with conventional amphotericin. Sangre 39(5): 389-392, 1994